<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RILUZOLE</span><br/>(ri-lu'zole)<br/><span class="topboxtradename">Rilutek<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anti-amyotrophic lateral sclerosis (als) agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Glutamate antagonist used for treating amyotrophic lateral sclerosis (ALS). Inhibits the presynaptic release of glutamic acid
         in the CNS.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness based on hypothesis that pathogenesis of ALS is related to injury of motor neurons by glutamate. Also protects
         neurons against the excitotoxicity of glutamic acid.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of ALS, may extend survival or time to tracheostomy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to riluzole; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic dysfunction, renal impairment; hypertension, history of other CNS disorders, pregnancy (category C). Safety and efficacy
         in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">ALS</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg q12h at least 1 h before or 2 h after meals<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at same time daily and at least 1 h before or 2 h after a meal. Do not give before/after a high-fat meal.</li>
<li>Store at room temperature; protect from bright light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Asthenia,</span> headache, back pain, malaise, arthralgia, weight loss, peripheral edema, flu-like syndrome. <span class="typehead"> CNS:</span> Hypertonia, depression, dizziness, dry mouth, insomnia, somnolence, circumoral paresthesia. <span class="typehead">CV:</span> Hypertension, tachycardia, phlebitis, palpitation. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">nausea,</span> vomiting, dyspepsia, anorexia, diarrhea, flatulence, stomatitis. <span class="typehead">Respiratory:</span> <span class="speceff-common">Decreased lung function,</span> rhinitis, increased cough, apnea, bronchitis, dysphagia, dyspnea. <span class="typehead">Skin:</span> Pruritus, eczema, alopecia, <span class="speceff-life">exfoliative dermatitis</span> (rare). <span class="typehead">Urogenital:</span> UTI. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">barbiturates</span>, <b>carbamazepine</b> may increase risk of hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract, 60% reaches systemic circulation. <span class="typehead">Peak:</span> Steady-state levels by day 5. <span class="typehead">Distribution:</span> 96% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P4501A2 (CYP1A2). <span class="typehead">Elimination:</span> 90% eliminated in urine. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor periodically Hct and Hgb, routine blood chemistries, and alkaline phosphatase. If febrile illness develops,
            monitor WBC count. Monitor liver function before and during course of therapy; evaluate ALT/SGPT every month for first 3 mo,
            every 3 mo for remainder of first year, and periodically thereafter.
         </li>
<li>Withhold drug and notify physician if liver enzymes are elevated.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not increase dose. There is no increased benefit from daily doses &gt;50 mg q12h.</li>
<li>Report any febrile illness to physician.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Learn common adverse effects and possible adverse interaction with alcohol.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>